BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• Business

  OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

  OSE Immunotherapeutics SA and Boehringer Ingelheim announced a major expansion of their partnership.

  May 22, 2024

   · 

  9 min read
• Business

  Evotec Reports Q1 2024 Results and Provides Corporate Update

  Evotec SE announced financial results and corporate updates for the first quarter 2024.

  May 22, 2024

   · 

  14 min read
• Business

  NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update

  NANOBIOTIX provided an update on operational progress and reported financial results for the first quarter of 2024.

  May 22, 2024

   · 

  4 min read
• Business

  deepull appoints Didier Deltort to its Board of Directors

  deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification for sepsis and other acute infections, announces the appointment of Didier Deltort to its Board of Directors.

  May 22, 2024

   · 

  2 min read
• Oxford Nanopore Technologies Collaborates With Twist Bioscience to Launch Pharmacogenomics Beta Programme and Advance Personalised Medicine

  Oxford Nanopore Technologies announced the launch of a new Pharmacogenomics Beta Program to advance personalised medicine, combining Twist Bioscience’s next generation sequencing target enrichment technology with Oxford Nanopore’s sequencing platform.

  May 22, 2024

   · 

  3 min read
• Business

  G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses

  G1 Therapeutics, Inc., a commercial-stage oncology company, and Deimos Biosciences, a portfolio company of Jupiter Bioventures, announced a global licensing agreement for lerociclib for radioprotective uses.

  May 22, 2024

   · 

  5 min read